🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "major milestone" in the effort against drug-resistant strains of the pathogen, according to scientists.

A Worldwide Public Health Issue

Cases of gonorrhoea are escalating worldwide, with estimates suggesting in excess of 82 million infections each year. Especially elevated rates are reported in the African continent and countries within the WHO's designated area, which spans from China and Mongolia to New Zealand. In England, cases have reached a historical peak, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an important and timely advancement in the context of rising global incidence, escalating drug resistance and the extremely scarce available drugs currently available.”

Health officials are increasingly worried about the increase in antibiotic-resistant strains. The WHO has classified it as a "critical concern". Recent surveillance showed that the effectiveness of primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Gain Clearance

Zoliflodacin, marketed under the name Nuzolvence, was authorized by the US FDA in mid-December for treating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Researchers hope that targeted use of this new drug will help delay the spread of drug resistance.

Another new antibiotic, originating from the pharmaceutical company GSK, was also approved in the same week. This treatment, which is also used to treat urinary tract infections, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin stemmed from a innovative non-profit model for drug creation. The charitable organization GARDP worked alongside the pharmaceutical company Innoviva to see it through.

“This authorization marks a huge turning point in the management of highly resistant gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Testing Results and Global Access

Based on findings published in a major medical journal, the new drug successfully treated more than 90% of cases of the STI. This places it at an comparable level with the typical regimen, which combines a dual-drug approach. The research involved over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, the non-profit has the ability to make available and distribute the drug in a wide range of developing nations.

Clinicians treating patients have expressed optimism. Access to a single-dose, oral treatment such as this is seen as a "critical tool" for gonorrhoea control. This is deemed essential to alleviate the strain of the infection for individuals and to stop the proliferation of untreatable gonorrhoea around the world.